COVID-19 vaccine comparison Biontech/Pfizer vs Moderna 2020

Comparison of the COVID-19 vaccines developed by BioNTech/Pfizer and Moderna as of November 2020

CharacteristicBioNTech/Pfizer (BNT162b2)Moderna (mRNA-1273)
Enrollment phase III 43,538 30,000
Cases in active cohort* 8 5
Cases in placebo cohort** 162 95
Efficacy (in %) 95 94.5
Manufacturing capacity 2020 (in million doses) 50 20
Manufacturing capacity 2021 (in million doses)*** 1,300 1,000
Download
Show detailed source information?
Register for free
Already a member?
Log in
Sources

Use Ask Statista Research Service

Release date

November 2020

Region

Worldwide

Survey time period

as of November 2020

Supplementary notes

* BioNTech/Pfizer: 1 severe case out of 8; Moderna: 0 severe case out of 5.
** BioNTech/Pfizer: 9 severe cases out of 162; Moderna: 11 severe cases out of 95.
*** Maximum estimate for Moderna.

Citation formats
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
  • Free Statistics
  • Premium Statistics

Professional Account

For teams of up to 5 people
$1,299 USD
per month, billed annually 1
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Leading companies trust Statista:
paypal google adobe pg samsung telekom

Related reports: Available to download in PDF or PPTX format

All datain one format
All data
in one format
Coronavirus: the pharma and medtech response

Everything on "Coronavirus: the pharma and medtech response" in one document: edited and divided into chapters, including detailed references.

Statista is a great source of knowledge, and pretty helpful to manage the daily work.
Christof Baron

Christof Baron
CEO, MindShare Germany

Statistics on " Coronavirus: the pharma and medtech response "

Other statistics that may interest you Coronavirus: the pharma and medtech response

Pharma - before the pandemic

6

Treatments and vaccines

8

Focus: BioNTech and Moderna

7

Opinions on COVID-19 vaccines

6

Business impact

4

Medtech - before the pandemic

5

Ventilators and testing

7

Further related statistics

19

Discover Statista

Need help with using Statista for your research? Tutorials and first steps

Further Content: You might find this interesting as well

Do you have any questions about our business solutions?

We provide you with detailed information about our Professional Account.

Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
  • Free Statistics
  • Premium Statistics

Professional Account

For teams of up to 5 people
$1,299 USD
per month, billed annually 1
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Learn more about how Statista can support your business.